retatrutide triple agonist weight loss trial Lilly orforglipron oral GLP-1 phase 3 Triple hormone receptor agonist retatrutide

This is higher than the general recommendation for tirzepatide users (1.0 to 1.2 g/kg) because of the additive muscle loss risk from autoimmune disease

From a safety perspective, brand-name medications are always a better option

Both ketosis and GLP-1 medications alter nutrient availability and metabolic function in ways that could affect fetal development or milk production

In the future, functional studies regarding certain metabolites should be conducted in vitro and in EAE models to provide stronger evidence that altered metabolic pathways coordinate the immune system to maintain the immunoinflammatory state of MS

Obes Surg 33(4):10171025 Jamal M, Alhashemi M, Dsouza C et al (2024) Semaglutide and tirzepatide for the management of weight recurrence after sleeve gastrectomy: a retrospective cohort study